Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

BACKGROUND: Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Richard W., Liu, Frank Xiaoqing, Shillington, Alicia C., Macahilig, Cynthia P., Diede, Scott J., Dave, Vaidehi, Harshaw, Qing, Saretsky, Todd L., Pickard, Alan Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561540/
https://www.ncbi.nlm.nih.gov/pubmed/32405921
http://dx.doi.org/10.1007/s11136-020-02520-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561540/
https://www.ncbi.nlm.nih.gov/pubmed/32405921
http://dx.doi.org/10.1007/s11136-020-02520-7

Ejemplares similares